Summary of Presentations from a ResMed-Sponsored Satellite Symposium, held at the 24th ERS Congress, Munich, Germany, on 8th September 2014
Chairperson: Wolfram Windisch1
Speakers: Jean-Louis Pepin,2 Thomas Köhnlein,3 Michael Dreher4
1. Cologne Merheim Medical Centre, Cologne, Germany
2. Hopital CHR Citadelle, Liege, Belgium
3. St. Georg Unternehmensgruppe, Leipzig, Germany
4. University Hospital Aachen, Aachen, Germany
Disclosure: Prof Windisch has received open research grants for his hospital and personal speaking fees from companies dealing with mechanical ventilation. Dr Pepin received personal fees from ResMed, Philips, Fisher & Paykel for lectures during congress symposia, and unrestricted grants from ResMed, Philips, and AGIRadom for conducting clinical studies. Dr Köhnlein has received grants and lecture fees from Deutsche Lungenstiftung, ResMed, Tyco, Weinmann, and Heinen und Löwenstein. Dr Dreher receives an open research grant from ResMed, and has received speaking fees and/or fees for advisory boards from: Weinmann, Respironics, Vivisol, Linde, ResMed, Breas, Novartis, Boehringer, Almirall, Actelion, and Chiesi.
Acknowledgements: Writing assistance was provided by Dr Ewen Legg of apothecom scopemedical.
Support: Medical writing assistance was funded by ResMed. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of ResMed.
Citation: EMJ Respir. 2014;2:41-48.
Prof Windisch opened the symposium on the efficacy of non-invasive ventilation (NIV) in the treatment of chronic obstructive pulmonary disease (COPD). Dr Jean-Louis Pepin summarised the evidence for efficacy of NIV in subgroups of COPD patients. Dr Thomas Köhnlein focused on a recently-published randomised trial showing a major reduction in mortality following NIV aimed at a marked reduction in carbon dioxide pressure (PaCO2), while Dr Michael Dreher illustrated the place of NIV in patients with recent exacerbations.